Monrovia's Xencor, which develops drugs for the treatment of cancer and autoimmune diseases, reported a 2021 net income of $82.6 million, or $1.37 per share, compared to a net loss of $69.3 million, or $(1.21) per share for the previous year. The company attributes the higher income primarily "to increased royalties and revenue recognized from collaborations."
- Brad Haugaard
No comments:
Post a Comment